# Bridging Critically Ill Patients With Cirrhosis to Transplant With Renal Replacement Therapy: A Multicenter Cohort Study

**Authors:** Filipe S. Cardoso, Minjee Kim, Beverley Kok, Richard Wunderink, Juan G. Abraldes, Constantine J. Karvellas

PMC · DOI: 10.1111/liv.70593 · Liver International · 2026-03-18

## TL;DR

This study finds that early renal replacement therapy in critically ill cirrhosis patients increases the chance of liver transplant but does not affect mortality.

## Contribution

The study provides new evidence on the role of early RRT in bridging cirrhosis patients to liver transplantation.

## Key findings

- About 27.7% of patients with cirrhosis required RRT on ICU days 1 to 3.
- Early RRT was associated with a higher likelihood of in-hospital liver transplant.
- Receipt of RRT on days 1 to 3 did not impact in-hospital mortality.

## Abstract

The efficacy of renal replacement therapy (RRT) in critically ill patients with cirrhosis remains dubious. We aimed to assess the impact of RRT on these patients' outcomes.

Multicenter retrospective cohort study including adult patients with cirrhosis admitted to intensive care units at University of Alberta Hospital (Edmonton, Canada) and Northwestern Memorial Hospital (Chicago, US) from January 2010 to December 2017. Primary exposure was receipt of RRT on ICU days 1 to 3. Fine and Gray multivariable regression with competing endpoints, in‐hospital liver transplant (LT) and mortality, was performed.

Among 898 patients, median (IQR) age was 57 (49–64) years and 539 (60.0%) were males. RRT on days 1 to 3 was used in 249 (27.7%) patients. Patients on RRT on days 1 to 3 had higher CLIF‐C‐ACLF scores on days 1 (61 vs. 55, p < 0.001) and 3 (59 vs. 50; p < 0.001) than others. During the hospital stay, 97 (10.8%) patients were transplanted and 296 (33.0%) died. Following adjustment for aetiology, number of extra‐renal organ failures, and year of inclusion, using mortality as competing event, RRT on days 1 to 3 was associated with higher hazard of LT (HR (95% CI) = 1.54 (1.02–2.32); p = 0.039). Conversely, using LT as competing event, RRT on days 1 to 3 was not associated with mortality (HR (95% CI) = 1.15 (0.90–1.47); p = 0.25).

Among critically ill patients with cirrhosis, early RRT, while offered more often to the sickest patients, was associated with a higher likelihood of receiving LT, but not with mortality.

On intensive care unit (ICU) days 1 to 3, about a quarter of patients with cirrhosis required renal replacement therapy (RRT).Patients on RRT in ICU days 1 to 3 had higher overall severity of disease than others.Following adjustment for aetiology, severity of disease, and year of inclusion, being on RRT on days 1 to 3 was independently associated with a higher hazard of being transplanted during the hospital stay.The receipt of RRT on days 1 to 3 did not impact in‐hospital mortality.

On intensive care unit (ICU) days 1 to 3, about a quarter of patients with cirrhosis required renal replacement therapy (RRT).

Patients on RRT in ICU days 1 to 3 had higher overall severity of disease than others.

Following adjustment for aetiology, severity of disease, and year of inclusion, being on RRT on days 1 to 3 was independently associated with a higher hazard of being transplanted during the hospital stay.

The receipt of RRT on days 1 to 3 did not impact in‐hospital mortality.

## Linked entities

- **Diseases:** cirrhosis (MONDO:0005155)

## Full-text entities

- **Diseases:** respiratory failure (MESH:D012131), ACLF (MESH:D065290), hyponatremia (MESH:D007010), Failure (MESH:D051437), alcoholic hepatitis (MESH:D006519), hepatic encephalopathy (MESH:D006501), liver disease (MESH:D008107), hepatitis C (MESH:D019698), liver dysfunction (MESH:D017093), hyperlactatemia (MESH:D065906), sepsis (MESH:D018805), Cirrhosis (MESH:D005355), Organ Failure (MESH:D009102), AKI (MESH:D058186), hyperammonemia (MESH:D022124), ALD (MESH:D008108), hypovolemia (MESH:D020896), Model (MESH:D004195), Acute-on (MESH:D000208), dying (MESH:D064806), Critically Ill (MESH:D016638), hepatocellular carcinoma (MESH:D006528), organ (MESH:D000092124), CLIF (MESH:D058625), death (MESH:D003643), HRS (MESH:D015211), parenchymal disease (MESH:D017563), acidosis (MESH:D000138), bleeding (MESH:D006470), infection (MESH:D007239), septic shock (MESH:D012772), -C (OMIM:211750)
- **Chemicals:** bilirubin (MESH:D001663), sodium (MESH:D012964), creatinine (MESH:D003404), alcohol (MESH:D000438), oxygen (MESH:D010100), lactate (MESH:D019344), MELD (-)
- **Species:** hepatitis C virus [taxon 11103], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12997015/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12997015/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12997015/full.md

---
Source: https://tomesphere.com/paper/PMC12997015